MyFinsight
Home
Blog
About
Proceeds from maturities
of securities
$29,910K
(-34.81%↓ Y/Y)
Proceeds from issuance of
common stock under...
$142K
(63.22%↑ Y/Y)
Proceeds from exercise of
stock options
$102K
(292.31%↑ Y/Y)
Net cash provided by
investing activities
$12,022K
(-64.63%↓ Y/Y)
Net cash provided by
financing activities
$244K
(115.93%↑ Y/Y)
Canceled cashflow
$17,888K
Net increase in
cash, cash...
-$1,460K
(-121.44%↓ Y/Y)
Canceled cashflow
$12,266K
Stock-based compensation
$1,158K
(-70.13%↓ Y/Y)
Amortization of operating
lease right-of-use...
$1,012K
(-56.68%↓ Y/Y)
Depreciation
$272K
(-70.50%↓ Y/Y)
Accrued expenses and
other liabilities
$248K
(-36.41%↓ Y/Y)
Amortization (accretion) of
premiums (discounts) on...
-$12K
(-101.22%↓ Y/Y)
Purchases of securities
$17,434K
(54.58%↑ Y/Y)
Purchases of property and
equipment
$454K
(-26.18%↓ Y/Y)
Net cash used in
operating activities
-$13,726K
(49.70%↑ Y/Y)
Canceled cashflow
$2,702K
Net loss
-$14,469K
(54.28%↑ Y/Y)
Operating lease
liabilities
-$1,057K
(53.94%↑ Y/Y)
Prepaid expenses and
other assets
$598K
(473.75%↑ Y/Y)
Accounts payable
-$304K
(-496.08%↓ Y/Y)
Back
Back
Cash Flow
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT)
source: myfinsight.com